ZebraMed Company Profile: Funding, Investors & Partnerships

ZebraMed

Pharma is blind to systemic human response, losing $100B annually and seeing 25% of new drugs receive black-box warnings for unforeseen toxicity. ZebraMed delivers systemic insight, cutting target-to-IND time by 50% and discovering targets based on human systemic response. Our Bio/AI OS industrializes multimodal zebrafish‚Äìhuman data to map mechanisms across diseases: 2x closer to human, interpretable AI (FDA/EMA-grade), with Tier 1 pharma traction and in vivo risk reduction.Pharma is blind to systemic human response, losing $100B annually and seeing 25% of new drugs receiv Show More

Alpha Score

40.9